好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2026 Annual Meeting | C17 - Progressive MS in Focus

Saturday 04/18/26
12:00 PM - 02:00 PM CDT Add To Calendar
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Seminar
Annette Wundes, MD, FAAN
Multiple Sclerosis
Participants shouldgain a comprehensive understanding of progressive MS, including basic concepts, metrics, and biomarkers and their clinical application; explore emerging strategies for remyelination and neuroprotection; discuss current and evolving approaches to DMT management; and evaluate strategies to promote brain health and optimize functional status in this patient cohort.
2.00 CME credits
Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice, Quality Improvement
Intermediate
Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Medical Student
Case-based, Didactic, Audience Participation
Event Timeline
12:00 PM - 12:03 PM CDT Introduction Progressive MS in Focus - Introduction and Logistics
Annette Wundes, MD, FAAN
12:03 PM - 12:31 PM CDT Speaker Basic Concepts, Metrics and Biomarkers - and How to Apply Them in Clinical Practice
Gloria Von Geldern, MD, FAAN
12:31 PM - 12:49 PM CDT Speaker Remyelination and Neuroprotection
Annette Wundes, MD, FAAN
12:49 PM - 01:17 PM CDT Speaker DMT Management in the Context of Progressive MS - Current State and Emerging Strategies
Gloria Von Geldern, MD, FAAN
01:17 PM - 01:45 PM CDT Speaker Promoting Brain Health and Optimal Functional Status
Annette Wundes, MD, FAAN
01:45 PM - 02:00 PM CDT Q&A Progressive MS in Focus - Q&A and Closing
Gloria Von Geldern, MD, FAAN
Faculty Disclosures
Annette Wundes, MD, FAAN The institution of Dr. Wundes has received research support from Benaroya Research Institute .
Gloria Von Geldern, MD, FAAN The institution of Dr. Von Geldern has received research support from Novartis. The institution of Dr. Von Geldern has received research support from Contineum Therapeutics. Dr. Von Geldern has received personal compensation in the range of $0-$499 for serving as a DSMB member with NIH, NINDS. Dr. Von Geldern has a non-compensated relationship as a editorial board member with MS and Related Disorders Journal that is relevant to AAN interests or activities.